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S100A6 preferentially labels type C nevus
cells and nevic corpuscles: additional
support for Schwannian differentiation of
intradermal nevi
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Melanocytic nevi demonstrate morphologic ‘‘matu-
ration’’ characterized by a progression from epitheli-
od ‘‘type A’’ cells in the papillary dermis to lympho-
cyte-like ‘‘type B’’ cells to Schwann-like ‘‘type C’’ cells
with progressive descent in the dermis.1,2 Over the
past century, the origin of the type C nevus cell has
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been a topic of considerable debate. Unna considered
the origin of dermal nevus cells to be derived from
epidermal melanocytes by a dropping off process re-
ferred to as ‘‘abtropfung’’.3 Yet, other investigators pro-
moted the theory that at least some dermal nevus cells
were derived from Schwann cells in the dermis, a pro-
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cess referred to as ‘‘hochsteigerung’’ or ascending of the
cells.4,5
Evidence in support of a melanocytic origin of der-
mal nevus cells is derived from ultrastructural, bio-
chemical, and light microscopic observations. In
1965, Gottlieb et al. demonstrated the close resem-
blance of nevus cells to melanocytes by ultrastructural
analysis.6 In 1971, Thorne et al. demonstrated tyro-
sinase activity in type C nevus cells by electron micro-
scopy using a modified DOPA reaction.7 Moreover,
age-related changes in intradermal nevi (IDN) also
support a single histogenesis from melanocytes.8–11
IDN show terminal ‘‘maturation’’ along a Schwann
cell differentiation pathway in progressing to type C
nevus cells. Goovaerts et al. proposed that ‘‘atrophy’’
is a more appropriate term than maturation for this
process, based on decrease in size and number of
most cellular constituents, except for mitochondria
and microfilaments.12 Evidence for Schwannian dif-
ferentiation comes from the close resemblance of type
C nevus cells to Schwann cells by light and electron
microscopy,4,13–15 presence of pseudo-Meissnerian
corpuscles (nevic corpuscles) in some IDN,4,13,16,17 in-
timate relationship between type C nevus cells and
complex networks of small unmyelinated axons,4,18,19
and similarities in immunophenotype between type C
nevus cells and Schwann cells.17,20,21
Immunohistochemical studies have shown that
type C nevus cells recapitulate Schwann cells in an
intermediate stage of differentiation, i.e. lack the abil-
ity to produce and maintain myelin. Aso et al. dem-
onstrated expression of a Schwann cell-associated
protein (AHMY-1), which reacted with P0 and P1
myelin proteins and myelin basic protein but not P2
myelin protein, in both type C nevus cells and nevic
corpuscles (NC).17 Some authors have shown that
type C nevus cells do not express myelin basic pro-
tein, a feature of terminally differentiated Schwann
cells, by immunohistochemistry.22,23 Reed et al.
showed that type C nevus cells and NC adopted
an intermediate, ‘‘premyelinating/promyelinating’’
Schwann cell phenotype based on expression of low-
affinity nerve growth factor receptor (p75-NGFR),
neural cell adhesion molecule (N-CAM/CD56), and
growth-associated phosphoprotein-43 (GAP-43).21
Prieto et al. demonstrated the relationship of small
axons to type C nevus cells and NC using an antibody
to the intermediate filament peripherin;24 however,
the type C nevus cells and NC did not label with
peripherin.24,25 Argenyi et al. demonstrated strong
p75-NGFR expression in NC, as well as in type C
nevus cells, and suggested that nerve growth factor
was important in development of NC, and that ‘‘neu-
ral differentiation’’ was a feature seen in some long-
standing nevi.26
Ultrastructurally, type C nevus cells show similar
features to spindle cells associated with NC, i.e.
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spindle cells possessing abundant cytoplasmic inter-
mediate filaments, discontinuous basal lamina, and
frequent pinocytotic vesicles.17,27 NC have laminated
cytoplasmic structures and, therefore, closely re-
semble Wagner-Meissner tactile bodies of the
skin.16,28,29
S100 protein is strongly expressed by cells of neural
crest origin, including melanocytes, Schwann cells,
and NC.30–34 Since the original isolation of S100 pro-
tein, a mixture of predominantly S100B and a lesser
amount of S100A1, from bovine brain extracts by
Moore in 1965,35 several other S100 calcium-binding
proteins have been discovered.36,37 S100A6 protein,
a.k.a. calcyclin, was discovered in 1986 by Calabretta
et al.38 This protein has been isolated from a variety
of normal cell types, including melanocytes, Schwann
cells and Schwann-like cells, Langerhans’ cells, der-
mal dendrocytes, some glandular epithelium, and
keratinocytes (weak).39–43 Some melanocytic nevi ex-
press S100A6 protein by immunohistochemistry.44
Since S100A6 protein has been reported in some
melanocytic nevi and Schwann cells, we evaluated the
pattern of S100A6 protein expression in IDN by im-
munohistochemistry to determine if the staining pat-
tern supports terminal differentiation along a
Schwann cell pathway. In addition, we evaluated a
variety of neural tumors thought to have a prominent
Schwann cell component to see if there was any dif-
ference in their expression of S100A6 protein.
Material and methods
Cases of IDN (38), neurofibroma (NF) (10),
Schwannoma (SCH) (3), solitary circumscribed neur-
oma/palisaded encapsulated neuroma (PEN) (2), and
granular cell tumor (GCT) (2) were retrieved from the
Dermatopathology Service and Archives at the New
York Hospital-Cornell University Weill Medical Col-
lege during the period of July 1998 to July 1999. IDN
that possessed spindled cells in the deep dermis or
had NC were specifically sought for inclusion in the
study.
Formalin-fixed, paraffin-embedded tissue sections,
approximately 4 m thick, were placed on charged
(plus), gray-frosted, 75 m capillary gap ChemMate/
BioTek slides (Ventana Medical Systems Inc., Tuscon,
AZ, USA). A 1-h capillary action-based immuno-
histochemical technique was employed as described
previously.45 The sections were deparaffinized, rehy-
drated and treated with pepsin for 10 min at 45æC.
Endogenous phosphatases were blocked using glacial
acetic acid (1%) for 10 min at room temperature. Pri-
mary antibodies to S100A6/clone CACY-100
(1:1000, mouse monoclonal; Sigma, St. Louis, MO,
USA) and S100B (1:1000, rabbit polyclonal; Dako,
Carpinteria, CA, USA) were applied to serial tissue
sections. Bound primary antibodies were detected
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Fig. 1. Preferential labeling of type C nevus cells and nevic corpuscles (inset) with anti-S100A6 (A) compared to more diffuse labeling of
type A-C cells and nevic corpuscles with anti-S100B (B).
using an streptavidin-alkaline phosphatase system.
The complexes were visualized with red chromogen
(SK-5100 kit; Vector Labs, Burlingame, CA, USA).
Tissue sections were counterstained with hema-
toxylin.
The different tissues were compared with respect
to types of cells stained and patterns of staining. Im-
munolabeling was determined to be present (π) or
absent (ª). Positive staining was then semiquantita-
tively graded as weak (1π) or strong (2π). The stain-
ing patterns were interpreted by two of the authors
(J.A.R. and D.R.F.).
Chi-square analysis was performed using Sigma
Stat software (Jandel Scientific, San Raphael, CA,
USA) run on a PC. Statistical significance was as-
signed to a p,0.05 value.
Results
Thirty-six of 38 (95%) IDN showed S100A6 protein
expression by type C nevus cells (28 strong, 8 weak)
in the deep portion of the dermal component. In con-
trast, 17 of 38 (45%) type A (0 strong, 17 weak) and
17 of 38 (45%) type B (4 strong, 13 weak) nevus cells
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showed S100A6 protein expression in the upper and
middle portions of the dermal component, respec-
tively (Fig. 1). The preferential S100A6 labeling of
type C nevus cells compared to types A and B nevus
cells achieved statistical significance (p,0.001).
Fig. 2. Diffuse and strong labeling of Schwann cells and Verocay
bodies in a Schwannoma.
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Fig. 3. Granular cell tumor showing absence of labeling with anti-S100A6 (left) but strong labeling with anti-S100B (right).
NC in 25 of 38 IDN (66%) showed positive staining
(19 strong, 6 weak) with anti-S100A6 compared to
type A (45%) or type B (45%) nevus cells (Fig. 1). This
difference did not reach statistical significance (pΩ
0.106), probably due to the lack of NC in 11 of 38
(29%) IDN. Two cases with NC did not stain with
anti-S100A6, but also did not have any staining with
anti-S100B.
All 10 NF, 3 SCH, and 2 PEN demonstrated strong
and diffuse positivity of the vast majority of spindled
cells in the tumors (Fig. 2). Interestingly, both GCT
did not label with anti-S100A6, but, as expected,
showed strong and diffuse staining with anti-S100B
(Fig. 3). On hematoxylin and eosin (H&E)-stained
sections, the polygonal tumor cells had small central
nuclei and abundant eosinophilic granular cytoplasm,
as is typical of a GCT. The S100B protein expression
excludes that either tumor is a fibrohistiocytic or
smooth muscle tumor with granular cell change.
Discussion
Neural tumors, characterized by the presence of
many Schwann cells, strongly expressed S100A6 cal-
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cium-binding protein in our study. This finding is not
surprising considering previous reports of increased
calcyclin gene expression in Schwann-like cells in
neuroblastoma cell lines,42 and Schwann cells of the
rat nervous system.43 The exception to these results
was the absence of anti-S100A6 labeling of either
GCT.
The histogenesis of the GCT has been debated for
many years. In recent years, clinical, histological, im-
munohistochemical (S100B expression), and ultra-
structural evidence has accumulated in support of a
neural origin for the vast majority of GCT.46–66 How-
ever, the exact neural cell from which the GCT is
derived has remained elusive. Some observers have
proposed that these tumors arise from the Schwann
cell,59–61 whereas other observers support an origin
from the perineurial fibroblast,67 or an undifferenti-
ated mesenchymal cell.68,69 We have demonstrated,
albeit in only two cases, that S100A6, which is com-
monly expressed by Schwann cells, is not present in
GCT. This immunophenotype finding in our GCT is
in keeping with other immunophenotypic findings
that are peculiar for terminally differentiated
Schwann cells.51,64,65,70,71 Additional studies includ-
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ing a broader panel of antibodies on a larger number
of GCT may shed light on whether these tumors are
derived from modified Schwann cells or some, as yet,
uncharacterized cell of the peripheral nerve sheath.
The preferential S100A6 expression of type C (vs.
type A and B) nevus cells demonstrated in this study
is additional support for terminal maturation of IDN
along a Schwann cell pathway of differentiation. In
addition, we demonstrated a tendency toward strong
labeling of NC (Wagner-Meissner-like corpuscles)
with anti-S100A6, a feature also consistent with
Schwann cell differentiation.
The presence of some S100A6 labeling of type A
and B nevus cells in IDN is clear evidence that mel-
anocytes express S100A6 protein and is consistent
with the previous observation by Böni et al.39 The
pattern of S100A6 protein expression compared to
S100B expression in IDN lends further support to the
opinion that dermal nevus cells are derived from nev-
omelanocytes in the epidermis. Moreover, some IDN,
especially those of long-standing duration, demon-
strate a predictable sequence of ‘‘maturation’’ in the
dermis that terminates with type C nevus cells. These
type C nevus cells share many phenotypic and ultra-
structural features with an intermediate stage
Schwann cell.4,13–15,17,20–23
In summary, we present compelling evidence,
through differential patterns of expression of two
S100 proteins, that the maturation of some melano-
cytic nevi recapitulates features of Schwann cell dif-
ferentiation. In addition, this is the first report, to our
knowledge, that demonstrates S100A6 protein ex-
pression in a variety of neural tumors of putative
Schwann cell origin by immunohistochemistry. The
absence of S100A6 protein expression by both GCT
suggests that these lesions have lost this feature of
Schwann cells, which is in keeping with other pheno-
typic findings that are peculiar for terminally differen-
tiated Schwann cells.
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